Searchable abstracts of presentations at key conferences on calcified tissues

ba0003oc1.2 | Phosphate metabolism, fracture repair and osteoarthritis | ECTS2014

Study of Hyp or Phex null male fetuses reveals that eightfold increased FGF23 does not alter fetal–placental phosphorus homeostasis or prenatal bone formation and mineralization

Ma Yue , Kirby Beth J. , Kovacs Christopher S.

Fibroblast growth factor-23 (FGF23) controls serum phosphorus by acting on the kidneys to excrete phosphorus and reduce calcitriol. These actions are well established in adults and children, but whether FGF23 regulates fetal phosphorus metabolism is unknown. We used X-linked Hyp or Phex null male fetuses to study the effect of excess FGF23 on fetal phosphorus metabolism. Phex+/− females and WT males were mated to generate WT, Phe...

ba0001oc2.1 | Bone quality and fracture repair - animal models | ECTS2013

Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of duchenne muscular dystrophy

Puolakkainen Tero , Ma Hongqiang , Pasternack Arja , Kainulainen Heikki , Ritvos Olli , Heikinheimo Kristiina , Hulmi Juha , Kiviranta Riku

Patients with Duchenne muscular dystrophy (DMD) carry a mutation in the dystrophin gene that leads to progressive muscle degeneration. In addition, DMD patients develop low bone mass especially in long bones and have high incidence of fractures. The underlying mechanisms for decreased bone mass remain unclear but muscle weakness and increased IL6 levels may play a role. Inhibition of activin/myostatin pathway has emerged as a novel approach to increase muscle mass and strength...

ba0005p296 | Osteoporosis: evaluation and imaging | ECTS2016

Predicting hip fracture type of elderly Asian patients with low-energy fall by volumetric BMD and femoral morphology from QCT

Su Yong-Bin , Cheng Xiao-Guang , Wang Ling , Ma Yi-Min

Introduction: Femoral neck fractures and trochanteric fractures are two major types of hip fractures. The BMD changing or hip strength analysis (HSA) of the two type fractures may be different. No research had focused on a large sample of Asian people. This study investigated the differences in BMD and morphologic features of the two type hip fractures of elderly Asian people from QCT.Methods: A total of 279 elderly Chinese patients with hip fractures du...

ba0007p34 | (1) | ICCBH2019

Bone metabolism and bone mineral density in Duchenne muscular dystrophy

Bautembach-Minkowska Joanna , Śledzińska Karolina , Wierzba Jolanta , Myśliwiec Małgorzata

Duchenne muscular dystrophy (DMD) is associated with an increased risk of bone fragility due to the adverse effects of prolonged glucocorticoid therapy and progressive muscle weakness on bone strength. The resultant osteoporosis, which predisposes to fragility fractures of both long bones and vertebrae, is a major cause for concern. We studied 70 boys with DMD mean age 10.74±3.83 years. Bone mineral density was measured by DXA scan on lumbar spine and total body and conte...

ba0003pp137 | Cell biology: osteoblasts and bone formation | ECTS2014

IGF1 stimulates protein synthesis by enhancing mRNA translation rate in osteoblasts

Bakker Astrid D. , Gakes Tom , Juffer Petra , Hogervorst Jolanda M.A. , de Wit Gerard M.J. , Klein-Nulend Jenneke , Jaspers Richard T.

IGF1 is an osteo-anabolic factor that stimulates osteogenic precursor cell differentiation. IGF1 is produced in bone in response to mechanical stimulation, but also in mechanically-stimulated muscle cells. IGF1 enhances the rate of mRNA translation in muscle cells via activation of the PI3K/AKT/mTOR pathway, thereby increasing in muscle mass. Therefore we hypothesized that IGF1 not just enhances osteogenic differentiation of precursors, but also stimulates protein syn...

ba0005p232 | Energy metabolism and bone, fat and bone | ECTS2016

Significant correlation between vasculopathy and bone mineral density in T2DM: new light shed on diabetic osteoporosis

Zhong Ni , Xu Mingxin , Su Junlei , Zhang Zhiyin , Cui Ran , Ma Yuelong , Sheng Chunjun , Zhang Ge , Sheng Hui , Qu Shen

Purpose: Osteoporosis (OP) aggravates with vasculature degeneration and improvement of vasculature could prevent OP. We, thus, hypothesize that vascular structure and function play an important role in the development of OP. Type 2 diabetes mellitus (T2DM) patients are vulnerable to vasculopathy, so T2DM were involved in this project to study the correlation between vasculopathy and bone mineral density (BMD).Methods: A total of 427 (180 in OP group; 247...

ba0001pp387 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Sclerostin associated with vertebral bone marrow fat in older men but not women

Ma Vivian , Li Xiaojuan , Sigurdsson Sigurdur , Eriksdottir Gudny , Hauksdottir Alda , Palermo Lisa , Hue Trisha , Lang Thomas , Harris Tamara , Rosen Clifford , Vittinghoff Eric , Siggeirsdottir Kristin , Sigurdsson Gunnar , Oskarsdottir Diana , Gudnason Vilmundur , Schwartz Ann

Previous studies found a negative correlation between vertebral bone marrow fat (MF) and bone density (BMD). Proposed mechanisms for this include i) a shift in stem cell lineage allocation from osteoblasts towards adipocytes, and ii) an increase in osteoclast-promoting cytokines with greater MF. However, little is known about the relationship between MF and bone markers. To assess these relationships in older adults, we used data from the AGES-Reykjavik cohort. MF was measured...

ba0007p151 | (1) | ICCBH2019

The safety and efficacy of denosumab versus zoledronic acid in the treatment of pediatric osteoporosis: a randomized controlled pilot trial

Robinson Marie-Eve , Ma Jinhui , Khan Nasrin , Khatchadourian Karine , Page Marika , Konji Victor , Ann Matzinger Mary , Shenouda Nazih , Jaremko Jacob L , Zuijdwijk Caroline , Jackowski Stefan , Saleh David , MacLeay Lynn , Siminoski Kerry , Ward Leanne M

Objectives: Denosumab (Dmab) is a monoclonal antibody targeting RANKL administered by sub-cutaneous injection. Given its convenient mode of administration, our goal was to assess the safety and efficacy of Dmab compared to intravenous zoledronic acid (ZA) in pediatric osteoporosis.Methods: In this one-year pilot study (NCT02632916), children 4–16 years with low-trauma fractures due to osteoporosis were randomized 1:1 to receive ZA 0.025 mg/kg or Dma...

ba0007p152 | (1) | ICCBH2019

An evaluation of the rebound phenomenon during denosumab therapy in children with low turnover osteoporosis

Robinson Marie-Eve , Ma Jinhui , Khan Nasrin , Khatchadourian Karine , Page Marika , Konji Victor , Ann Matzinger Mary , Shenouda Nazih , Jaremko Jacob L , Zuijdwijk Caroline , Jackowski Stefan , Saleh David , MacLeay Lynn , Siminoski Kerry , Ward Leanne M

Objectives: Denosumab (Dmab) is a monoclonal antibody targeting RANKL administered by sub-cutaneous injection. Recent reports have raised concern about the ‘rebound phenomenon’ (hypercalcemia and increases in bone turnover markers, BTM) following Dmab in adults, and during treatment in children with osteogenesis imperfecta. The purpose of this report was to explore this phenomenon in children with osteoporosis associated with lower bone turnover.<p class="abstext...